Nymox Pharmaceutical (NYMX) Closes Enrollment in Second NX-1207 Phase 3 as BPH Treatment
Tweet Send to a Friend
Nymox Pharmaceutical (Nasdaq: NYMX) announced the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
